Adjuvant capable of improving dendritic cell vaccine efficiency

A technology of dendritic cells and vaccine adjuvants, applied in the field of new vaccine adjuvants, can solve problems such as functional impact

Inactive Publication Date: 2009-04-15
THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA +1
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether evodiamine will affect the function of DC, an important member of the immune system, has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Adjuvant capable of improving dendritic cell vaccine efficiency
  • Adjuvant capable of improving dendritic cell vaccine efficiency
  • Adjuvant capable of improving dendritic cell vaccine efficiency

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1, the physicochemical property of evodiamine

[0056] Molecular weight 303.4Da, insoluble in water, soluble in dimethyl sulfoxide, ethanol, ether, chloroform and other organic solvents, melting point is 278-279 ℃.

[0057] Structural formula see figure 1.

Embodiment 2

[0058] Example 2. The experiment that evodiamine-treated DC promotes the proliferation of T cells

[0059] The bone marrow cells of Balb / c mice were isolated, and the immature DC cells (iDC) induced by GM-CSF for 10 days were treated with different factors and divided into: control group (I), evodiamine group (Evo) (II), Endotoxin (LPS) group (III), Evo+LPS (IV). The final concentration of Evo was 10 μM, and the final concentration of LPS was 1 μg / ml, and the effect was 24 hours. Collect the above four groups of cells, add mitomycin C (final concentration is 25 μg / ml) and place in CO 2 After incubating in an incubator at 37°C for 30 minutes, centrifuge and count, and adjust the cell concentration to 1×10 with 1640 culture medium containing calf serum. 6 cells / ml were used as stimulator cells, and 100 μl / well was added to a 96-well culture plate. The prepared C57BL / 6 mouse spleen non-adherent cells were centrifuged and counted, and the concentration was adjusted to 4×10 6...

Embodiment 3

[0061] Example 3. Synergistic Effect of Evodiamine on DC Vaccine Repairing Damaged Spinal Cord

[0062] 1. Evaluation of motor function in each treatment group of mice with spinal cord injury

[0063] Adult BALB / c mice, using microsurgical arterial clips to make a T10 segmental severe clamp injury SCI model; in addition, the bone marrow cells of the same line of mice were induced into immature DC (simple DC group), and some immature DC loaded spinal cord Homogenized protein (100 μg / mL) for 2 hours (DC vaccine group), some immature DCs were treated with evodiamine (10 μM) for 24 hours and then loaded with spinal cord homogenate protein for 2 hours (Evo+DC vaccine group), washed with fresh DC medium, Store on ice for later use. Before injection, the cells were centrifuged and suspended in PBS (5×10 5 / 5μl PBS for local injection, 1×10 6 / 0.3ml PBS for intraperitoneal injection). Experimental animals were divided into 3 groups to receive the above 3 kinds of DC treatment re...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an adjuvant for improving the effectiveness of a dendritic cell vaccine, which is a traditional Chinese medicine monomer, namely evodiamine.

Description

technical field [0001] The invention relates to a new type of vaccine adjuvant which can improve the efficiency of dendritic cell vaccine and the effect of cellular immunity. The adjuvant is a traditional Chinese medicine monomer-evodiamine. Background technique [0002] Dendritic cells (DC), as the strongest antigen-presenting cells and the only antigen-presenting cells that can activate naive T cells, have become one of the focuses in the field of biomedicine. [0003] Compared with other antigen-presenting cells such as B cells, macrophages (Mφ), and Langerhans cells (Langerhans cells, LC), DCs have inherent advantages as vaccines: (1) DCs have the ability to present antigens strongest cells. In addition to ingesting antigens through phagocytosis and pinocytosis, DCs also have special membrane receptors for ingesting and transporting antigens, so DCs can efficiently capture the corresponding antigens at very low concentrations. Some scholars have proved that the ability...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/00A61P31/04A61P31/10A61P31/12A61P25/00A61P35/00
Inventor 梁华平李小凤姚咏明韩健
Owner THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap